ClinicalTrials.gg
CompletedNCT04919642Updated Jun 25, 2024

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

A Phase 2 interventional study of TT-00420 in Cholangiocarcinoma, FGFR2 Fusion and FGFR2 Gene Mutation, sponsored by TransThera Sciences (Nanjing), Inc.. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
114th of 279
55 · median 44
Started
2021
with 24 others
Phase 2
94 of 328
20 open now
Registered
214th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 114th largest by enrollment of the 279 interventional ones that give a count, is one of 25 that started in 2021, is one of 94 in phase 2, and was the 214th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

Read the detailed description

This is a Phase II, open-label study to evaluate the efficacy and safety of TT00420 in patients with advanced/metastatic and surgically unresectable cholangiocarcinoma (CCA) with 1) FGFR 2 fusions who failed prior FGFR inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment, 3) with other FGFR alterations, or 4) whose tumors do not contain a detectable FGFR alteration.

03

Conditions studied

  • Cholangiocarcinoma
  • FGFR2 Fusion
  • FGFR2 Gene Mutation
  • FGFR1 Alteration
  • FGFR3 Alteration

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age, at the time of signing
  2. or cytologically documented advanced/ or surgically unresectable cholangiocarcinoma who have received at least one line of prior systemic chemotherapy. Patients will be assigned to 1 of 4 cohorts:

    • Cohort A1: FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor
    • Cohort A2: FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor
    • Cohort B: other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
    • Cohort C: negative for FGFR alterations (FGFR wild-type)
  3. At least one as defined by V1.1 criteria for solid tumors5
  4. Documentation of FGFR gene alteration status
  5. (ECOG) performance status of 0 or 1
  6. Adequate organ function confirmed at screening and within 10 days of initiating treatment, as evidenced by:

    • (ANC) ≥ 1.5 x 10\^9/L
    • (Hgb) ≥ 8 g/dl
    • (plt) ≥ 75 x 10\^9/L
    • /serum glutamate oxaloacetate transaminase (AST/SGOT) and alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤ 2.5 x (ULN) or ≤ 5.0 x ULN if liver metastases are present
    • Total ≤ 1.5 x ULN
    • Calculated creatine clearance ≥ 50 mL/min ( formula
  7. Negative pregnancy test within 72 hours before starting study treatment in all premenopausal women and women \< 12 months after the onset of menopause
  8. Must agree to take sufficient methods to avoid pregnancy (including male and female participants) during the study and until at least 6 months after ceasing study treatment
  9. Able to sign informed consent and comply with the protocol

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Women of (WOCBP) who do not use adequate
  3. Patients with untreated brain or central nervous system (CNS) or brain/ that have progressed (e.g. evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain/CNS metastases) Note: Patients with treated brain metastases that are off and have been clinically stable for 28 days are eligible for enrollment.
  4. Patients with a known concurrent that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, carcinoma in situ of the cervix or other noninvasive or indolent malignancy that has previously undergone potentially curative therapy.
  5. Patients with the following mood disorders as judged by the Investigator or a psychiatrist:

    • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia; a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
    • ≥ grade 3 anxiety
  6. Impaired cardiac function or significant diseases, including but not limited to any of the following:

    • (LVEF) \< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)
    • Congenital long syndrome
    • QTcF ≥ 480 msec on screening
    • Unstable angina pectoris ≤ 3 months prior to starting study drug
    • Acute myocardial infarction ≤ 3 months prior to starting study drug
  7. Patients with uncontrolled hypertension (defined as blood pressure of ≥ 150 mmHg systolic and/or ≥ 90 mmHg diastolic at Screening)
  8. Patients with:

    • unresolved diarrhea ≥ CTCAE grade 2, or
    • impairment of gastrointestinal (GI) function, or
    • GI disease that may significantly alter the absorption of TT-00420.
  9. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. uncontrolled hypertriglyceridemia [triglycerides > 500 mg/dL], or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
  10. Patients who have received chemotherapy, targeted therapy, or immunotherapy ≤ 5 half-lives or 3 weeks, whichever is shorter, (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug
  11. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy
  12. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy
  13. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants
  14. Patients who are currently receiving treatment with strong inhibitors or inducers, or sensitive substrates of CYP3A4 ≤ 2 weeks prior to starting study drug.
  15. Patients who are using a proton pump inhibitor within 4 days prior to the start of study therapy or a histamine-2 blocker within 2 days prior to the start of study therapy.
  16. Known diagnosis of (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion and Sponsor approval)
  17. Evidence of active infection with or that is not adequately controlled. For patients with known prior history of Hepatitis B or Hepatitis C, enrollment may be allowed per investigator's discretion and Sponsor approval.
  18. Inability to swallow or tolerate oral medication
  19. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Cohort A1

    FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor

    Drug: TT-00420

  • Experimental
    Cohort A2

    FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor and discontinued due to disease progression

    Drug: TT-00420

  • Experimental
    Cohort B

    Other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions

    Drug: TT-00420

  • Experimental
    Cohort C

    Negative for FGFR alterations (FGFR wild-type)

    Drug: TT-00420

Interventions

  • TT-00420 tablet, administered orally once daily

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in patients with FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor (Cohort A1)

    The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  2. ORR in patients with FGFR2 fusions who have responded (CR or PR) on at least one previous treatment with an FGFR inhibitor and discontinued due to progressive disease (Cohort A2)

    Time frame: Through study completion, an average of 9 months.

  3. ORR in patients with FGFR alterations other than FGFR2 fusions (Cohort B)

    Time frame: Through study completion, an average of 9 months.

  4. ORR in patients without FGFR alterations (wild-type FGFR mutation status) (Cohort C)

    Time frame: Through study completion, an average of 9 months.

Secondary outcomes

  1. ORR in all patients with FGFR alterations (Cohorts A and B)

    Time frame: Through study completion, an average of 9 months.

  2. Progression Free Survival (PFS) (All Cohorts)

    Time frame: From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  3. Disease Control Rate (DCR) (All Cohorts)

    Defined as CR + PR + stable disease (SD)

    Time frame: Through study completion, an average of 9 months.

  4. Overall Survival (OS) (All Cohorts)

    Time frame: From first study drug administration until the date of death from any cause, assessed up to 24 months

  5. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (All Cohorts)

    As assessed per CTCAE version 5.0

    Time frame: Up to 30 days from study discontinuation

  6. Concentration of TT-00420 at Protocol-Specified Timepoints (All Cohorts)

    Time frame: From Cycle 1 to Cycle 4, an average of 4 months (each cycle is 28 days)

Other outcomes

  1. Genetic Alteration Status

    Evaluation of biomarkers, including but not limited to, FGFR mutation status

    Time frame: Through study completion, an average of 9 months

07

Study locations

32 sites
  • Providence Cancer Center
    Anchorage, Alaska 99508, United States
  • City of Hope
    Duarte, California 91010, United States
  • University of California, Los Angeles, School of Medicine
    Santa Monica, California 90404, United States
  • USO Oncology Network- Rocky Mountain Cancer Centers
    Denver, Colorado 80218-1237, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • University of Chicago Medical Center - Duchossis Center for Advanced Medicine
    Chicago, Illinois 60637-1426, United States
  • University of Maryland - Marlene and Stewart Greenebaum Cancer Center
    Baltimore, Maryland 21250, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health Center
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Comprehensive Cancer Center of Nevada
    Las Vegas, Nevada 89169, United States
  • Summit Medical Group - Florham Park Campus
    Florham Park, New Jersey 07932, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14203, United States
  • Ruttenberg Treatment Center - Mount Sinai
    New York, New York 10029, United States
  • USOR Oncology Network- New York Oncology
    New York, New York 12208, United States
  • Stony Brook University - Long Island Cancer Center
    Stony Brook, New York 11794, United States
  • University of Cincinnati Cancer Institute
    Cincinnati, Ohio 45219, United States
  • University Hospitals Seidman Cancer Center
    Cleveland, Ohio 44106, United States
  • USO Oncology Network-Northwest Cancer Specialists, P.C.
    Portland, Oregon 97227, United States
  • Medical College of South Carolina
    Charleston, South Carolina 29425, United States
  • The University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Sarah Cannon Research Institute at Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Parkland Health & Hospital System
    Dallas, Texas 75235, United States
  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
    Dallas, Texas 75235, United States
  • Houston Methodist Hospital - Outpatient Center
    Houston, Texas 77030, United States
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • USO Oncology Network-Texas Oncology
    Tyler, Texas 75702-8363, United States
  • USO Oncology Network-Virginia Oncology Associates - Brock Cancer Center - Norfolk
    Norfolk, Virginia 23502-2824, United States
  • USO Oncology Network-Oncology and Hematology Associates of Southwest Virginia, Inc.
    Roanoke, Virginia 24014, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53705, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Feb 2024, 26 months.

Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jun 9, 2021
StartActual
Dec 7, 2021
Primary completionActual
Feb 28, 2024
CompletionActual
Feb 28, 2024
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04919642
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Jun 9, 2021
Start date
Dec 7, 2021
Primary completion
Feb 28, 2024
Completion
Feb 28, 2024
Last update
Jun 25, 2024

Study contacts

Milind Javle, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion